Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer.
Feb 2007 - Thyroid; 17(1):1050-7256 [PMID:17274750]
[Kuwabara K] [Nishishita T] [Morishita M] [Oyaizu N] [Yamashita S] [Kanematsu T] [Obara T] [Mimura Y] [Inoue Y] [Kaminishi M] [Kaga K] [Amino N] [Kitaoka M] [Ito K] [Miyauchi A] [Noguchi S] [Uchimaru K] [Akagawa E] [Watanabe N] [Takahashi TA] [Sato K] [Inazawa T] [Nakaoka T] [Yamashita N]

Combined use of dendritic cells enhances specific antileukemia immunity by leukemia cell-derived heat shock protein 70 in a mouse model with minimal residual leukemia cells.
Dec 2006 - Int. J. Hematol.; 84(5):0925-5710 [PMID:17189229]
[Iuchi Y] [Torimoto Y] [Sato K] [Tamura Y] [Jimbo J] [Inamura J] [Shindo M] [Ikuta K] [Ohnishi K] [Kohgo Y]

Thyroglobulin-pulsed human monocyte-derived dendritic cells induce CD4+ T cell activation.
Dec 2003 - Int. J. Mol. Med.; 13(1):1107-3756 [PMID:14654967]
[Morishita M] [Uchimaru K] [Sato K] [Ohtsuru A] [Yamashita S] [Kanematsu T] [Yamashita N]

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
Sep 2003 - Melanoma Res.; 13(5):0960-8931 [PMID:14512794]
[Nagayama H] [Sato K] [Morishita M] [Uchimaru K] [Oyaizu N] [Inazawa T] [Yamasaki T] [Enomoto M] [Nakaoka T] [Nakamura T] [Maekawa T] [Yamamoto A] [Shimada S] [Saida T] [Kawakami Y] [Asano S] [Tani K] [Takahashi TA] [Yamashita N]